<DOC>
	<DOCNO>NCT00012363</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient metastatic recurrent cancer esophagus .</brief_summary>
	<brief_title>S0101 Gemcitabine Irinotecan Treating Patients With Metastatic Recurrent Cancer Esophagus</brief_title>
	<detailed_description>OBJECTIVES : - Determine 6-month survival rate patient metastatic recurrent carcinoma esophagus gastroesophageal junction treat gemcitabine irinotecan . - Determine qualitative quantitative toxic effect regimen patient . OUTLINE : Patients receive gemcitabine IV 30 minute irinotecan IV 90 minute day 1 8 . Treatment repeat every 21 day least 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 30-55 patient accrue study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic recurrent carcinoma esophagus gastroesophageal junction Squamous cell carcinoma OR Adenocarcinoma No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 100 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Not specify Renal : Creatinine great 1.5 time upper limit normal Cardiovascular : No uncontrolled hypertension No unstable angina No symptomatic congestive heart failure No myocardial infarction within past 6 month No serious uncontrolled cardiac arrhythmia Gastrointestinal : No active inflammatory bowel disease No significant bowel obstruction No chronic diarrhea Other : Not pregnant nursing Fertile patient must use effective contraception No active infection require systemic therapy No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy : At least 28 day since prior biologic therapy No prior biologic therapy metastatic recurrent disease No concurrent sargramostim ( GMCSF ) No concurrent immunotherapy tumor Chemotherapy : At least 28 day since prior chemotherapy No prior chemotherapy metastatic recurrent disease No prior gemcitabine irinotecan Prior adjuvant neoadjuvant chemotherapy time initial diagnosis localize disease allow No concurrent chemotherapy tumor Endocrine therapy : See Disease Characteristics At least 28 day since prior endocrine therapy No prior endocrine therapy metastatic recurrent disease No concurrent hormonal therapy tumor Radiotherapy : At least 28 day since prior radiotherapy No prior radiotherapy metastatic recurrent disease Prior adjuvant neoadjuvant radiotherapy time initial diagnosis localize disease allow No concurrent radiotherapy tumor Surgery : Prior thoracoabdominal surgery allow At least 3 week since prior surgery recover Other : No concurrent anticancer therapy tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>